Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
63 hedge funds and large institutions have $71.2M invested in Neos Therapeutics, Inc in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 6 closing their positions.
71% more capital invested
Capital invested by funds: $41.7M → $71.2M (+$29.5M)
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding
Funds holding: 63 → 63 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less call options, than puts
Call options by funds: $76K | Put options by funds: $91K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.98M |
| 2 |
Goldman Sachs
New York
|
+$2.07M |
| 3 |
DM
Deerfield Management
New York
|
+$1.33M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$707K |
| 5 |
Millennium Management
New York
|
+$552K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$2.36M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$1.28M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$248K |
| 4 |
PCM
Proxima Capital Management
New York
|
-$176K |
| 5 |
BlackRock
New York
|
-$150K |
NEOS Hedge Fund Activity: Q1 2019 in Review
63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q1 2019, worth a combined $71.2M — up 71% from $41.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NEOS positions and 6 closed out — a net gain of 1 holder — while 26 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.98M. The largest seller was Broadfin Capital, cutting an estimated $2.36M.
- 63 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $71.2M of Neos Therapeutics, Inc stock for Q1 2019, up 71% quarter-over-quarter.
- 7 funds opened new Neos Therapeutics, Inc positions in Q1 2019 and 6 closed out, a net change of +1 holder.
- The largest Neos Therapeutics, Inc buyer in Q1 2019 was Vanguard Group, an estimated $2.98M added.
- The largest Neos Therapeutics, Inc seller in Q1 2019 was Broadfin Capital, an estimated $2.36M sold.
Based on aggregated 13F filings for Q1 2019.